ARTICLE | Company News
Inflection Biosciences, Spanish National Cancer Research Centre (CNIO) deal
June 10, 2013 7:00 AM UTC
Inflection received exclusive, worldwide rights from CNIO to develop and commercialize preclinical kinase inhibitors to treat cancer. The compounds include pan-Pim (PIM) kinase; phosphoinositide 3-ki...